GAINESVILLE, Fla.--(BUSINESS WIRE)--Feb. 14, 2006--RegenMed (www.regenmedbio.com), a development-stage biotechnology company, today announced that the company’s anti-SDF-1 treatment prevents retinal neovascularization, a condition that causes blood vessels in the retina to leak fluid or blood and grow branches and scar tissue. This can lead to blurred, distorted vision in primates.
